Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. oncogene 
3. original article 
4. article
Show authors
•  Original Article
•  Published: 04 February 2013


Ink4a/Arf−/− and
HRAS(G12V) transform mouse
mammary cells into triple-
negative breast cancer
containing tumorigenic
CD49f− quiescent cells
•  K Kai1,2,3,
•  T Iwamoto2,
•  T Kobayashi3,
•  Y Arima3,
•  Y Takamoto3,
•  N Ohnishi3,
•  C Bartholomeusz1,2,
•  R Horii4,
•  F Akiyama4,
•  G N Hortobagyi2,
•  L Pusztai1,2,
•  H Saya
3 &
•  …
•  N T Ueno
1,2 
Oncogene volume 33, pages 440–448 (2014)Cite this article
•  1754 Accesses
•  8 Citations
•  7 Altmetric
•  Metrics details
Subjects


•  Breast cancer
•  Cancer models
•  Tumour heterogeneity
Abstract
Intratumoral heterogeneity within individual breast tumors is a
well-known phenomenon that may contribute to drug resistance.
This heterogeneity is dependent on several factors, such as types of
oncogenic drivers and tumor precursor cells. The purpose of our
study was to engineer a mouse mammary tumor model with
intratumoral heterogeneity by using defined genetic perturbations.
To achieve this, we used mice with knockout (–/–) of Ink4a/Arf, a
tumor suppressor locus; these mice are known to be susceptible to
non-mammary tumors such as fibrosarcoma. To induce mammary
tumors, we retrovirally introduced an oncogene, HRAS(G12V), into
Ink4a/Arf−/− mammary cells in vitro, and those cells were
inoculated into syngeneic mice mammary fat pads. We observed
100% tumorigenesis. The tumors formed were negative for estrogen
receptor, progesterone receptor and HER2. Further, they had
pathological features similar to those of human triple-negative
breast cancer (TNBC) (for example, pushing borders, central
necrosis). The tumors were found to be heterogeneous and included
two subpopulations: CD49f− quiescent cells and CD49f+cells.
Contrary to our expectation, CD49f− quiescent cells had high
tumor-initiating potential and CD49f+cells had relatively low
tumor-initiating potential. Gene expression analysis revealed that
CD49f− quiescent cells overexpressed epithelial-to-mesenchymal
transition-driving genes, reminiscent of tumor-initiating cells and
claudin-low breast cancer. Our animal model with intratumoral
heterogeneity, derived from defined genetic perturbations, allows
us to test novel molecular targeted drugs in a setting that mimics
the intratumoral heterogeneity of human TNBC.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution


Access options
 Access through your institution
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Learn more
Buy this article
•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions
•  Read our FAQs
•  Contact customer support
Figure 1
[image]
Figure 2
[image]
Figure 3
[image]
Figure 4
[image]
Figure 5


[image]
Similar content being viewed by others
[image]
Single-cell RNA sequencing reveals the effects of
mental stress on mouse mammary tumors and the
tumor microenvironment
Article Open access 16 July 2025
[image]
Proteomic analysis of archival breast cancer clinical
specimens identifies biological subtypes with distinct
survival outcomes
Article Open access 16 February 2022
[image]
An inflamed tumor cell subpopulation promotes
chemotherapy resistance in triple negative breast
cancer
Article Open access 14 February 2024
References
1. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R,
Kuo WL et al. Genomic and transcriptional aberrations linked
to breast cancer pathophysiologies. Cancer Cell 2006; 10:
529–541.
Article  CAS  PubMed  Google Scholar 
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees
CA et al. Molecular portraits of human breast tumours. Nature
2000; 406: 747–752.


Article  CAS  PubMed  Google Scholar 
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D,
Gronroos E et al. Intratumor heterogeneity and branched
evolution revealed by multiregion sequencing. N Engl J Med
2012; 366: 883–892.
Article  CAS  PubMed  PubMed Central  Google Scholar 
4. Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells,
cancer, and cancer stem cells. Nature 2001; 414: 105–111.
Article  CAS  PubMed  Google Scholar 
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ,
Clarke MF . Prospective identification of tumorigenic breast
cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–3988.
Article  CAS  PubMed  PubMed Central  Google Scholar 
6. Shipitsin M, Campbell LL, Argani P, Weremowicz S,
Bloushtain-Qimron N, Yao J et al. Molecular definition of
breast tumor heterogeneity. Cancer Cell 2007; 11: 259–273.
Article  CAS  PubMed  Google Scholar 
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire
J et al. Identification of a cancer stem cell in human brain
tumors. Cancer Res 2003; 63: 5821–5828.
CAS  PubMed  Google Scholar 
8. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI et al.
Clinical and biological implications of CD133-positive and
CD133-negative cells in glioblastomas. Lab Invest 2008; 88:
808–815.
Article  CAS  PubMed  Google Scholar 
9. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC,
Lindeman GJ, Visvader JE . The mammary progenitor marker
CD61/beta3 integrin identifies cancer stem cells in mouse


models of mammary tumorigenesis. Cancer Res 2008; 68:
7711–7717.
Article  CAS  PubMed  Google Scholar 
10. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F,
Edwards D et al. Identification of tumor-initiating cells in a
p53-null mouse model of breast cancer. Cancer Res 2008; 68:
4674–4682.
Article  CAS  PubMed  PubMed Central  Google Scholar 
11. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G
et al. Isolation and molecular characterization of cancer stem
cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008;
26: 364–371.
Article  CAS  PubMed  Google Scholar 
12. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM,
Sjolund A et al. Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating
features. Proc Natl Acad Sci USA 2009; 106: 13820–13825.
Article  CAS  PubMed  PubMed Central  Google Scholar 
13. Sherr CJ . The INK4a/ARF network in tumour suppression.
Nat Rev Mol Cell Biol 2001; 2: 731–737.
Article  CAS  PubMed  Google Scholar 
14. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho
RA . Role of the INK4a locus in tumor suppression and cell
mortality. Cell 1996; 85: 27–37.
Article  CAS  PubMed  Google Scholar 
15. Debies MT, Gestl SA, Mathers JL, Mikse OR, Leonard TL,
Moody SE et al. Tumor escape in a Wnt1-dependent mouse
breast cancer model is enabled by p19Arf/p53 pathway
lesions but not p16 Ink4a loss. J Clin Invest 2008; 118: 51–63.


Article  CAS  PubMed  Google Scholar 
16. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD
. Biological properties of human c-Ha-ras1 genes mutated at
codon 12. Nature 1984; 312: 71–75.
Article  CAS  PubMed  Google Scholar 
17. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel
DE, Boss GR . Ras activation in human breast cancer. Breast
Cancer Res Treat 2000; 62: 51–62.
Article  CAS  PubMed  Google Scholar 
18. Eckert LB, Repasky GA, Ulku AS, McFall A, Zhou H, Sartor CI
et al. Involvement of Ras activation in human breast cancer
cell signaling, invasion, and anoikis. Cancer Res 2004; 64:
4585–4592.
Article  CAS  PubMed  Google Scholar 
19. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M,
Ronzoni S et al. Biological and molecular heterogeneity of
breast cancers correlates with their cancer stem cell content.
Cell 2010; 140: 62–73.
Article  CAS  PubMed  Google Scholar 
20. Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, Kaba M et
al. Enrichment of a population of mammary gland cells that
form mammospheres and have in vivo repopulating activity.
Cancer Res 2007; 67: 8131–8138.
Article  CAS  PubMed  Google Scholar 
21. Rakha EA, Ellis IO . Triple-negative/basal-like breast cancer:
review. Pathology 2009; 41: 40–47.
Article  PubMed  Google Scholar 
22. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK,
Asselin-Labat ML et al. Generation of a functional mammary


gland from a single stem cell. Nature 2006; 439: 84–88.
Article  CAS  PubMed  Google Scholar 
23. Cardiff RD . The pathology of EMT in mouse mammary
tumorigenesis. J Mammary Gland Biol Neoplasia 2010; 15:
225–233.
Article  PubMed  PubMed Central  Google Scholar 
24. Zhang D, Lafortune TA, Krishnamurthy S, Esteva FJ,
Cristofanilli M, Liu P et al. Epidermal growth factor receptor
tyrosine kinase inhibitor reverses mesenchymal to epithelial
phenotype and inhibits metastasis in inflammatory breast
cancer. Clin Cancer Res 2009; 15: 6639–6648.
Article  CAS  PubMed  PubMed Central  Google Scholar 
25. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A,
Moreno-Bueno G, Palacios J . Epithelial-mesenchymal
transition in breast cancer relates to the basal-like phenotype.
Cancer Res 2008; 68: 989–997.
Article  CAS  PubMed  Google Scholar 
26. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang
CY et al. Gene pathways associated with prognosis and
chemotherapy sensitivity in molecular subtypes of breast
cancer. J Natl Cancer Inst 2011; 103: 264–272.
Article  CAS  PubMed  Google Scholar 
27. Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM et
al. Validation and clinical utility of a 70-gene prognostic
signature for women with node-negative breast cancer. J Natl
Cancer Inst 2006; 98: 1183–1192.
Article  CAS  PubMed  Google Scholar 
28. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F
et al. Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet 2005;


365: 671–679.
Article  CAS  Google Scholar 
29. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H
et al. The humoral immune system has a key prognostic
impact in node-negative breast cancer. Cancer Res 2008; 68:
5405–5413.
Article  CAS  PubMed  Google Scholar 
30. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi
D et al. Purification and unique properties of mammary
epithelial stem cells. Nature 2006; 439: 993–997.
Article  CAS  PubMed  Google Scholar 
31. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al.
Aberrant luminal progenitors as the candidate target
population for basal tumor development in BRCA1 mutation
carriers. Nat Med 2009; 15: 907–913.
Article  CAS  PubMed  Google Scholar 
32. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM,
Goodell MA . Sca-1(pos) cells in the mouse mammary gland
represent an enriched progenitor cell population. Dev Biol
2002; 245: 42–56.
Article  CAS  PubMed  Google Scholar 
33. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et
al. PML targeting eradicates quiescent leukaemia-initiating
cells. Nature 2008; 453: 1072–1078.
Article  CAS  PubMed  PubMed Central  Google Scholar 
34. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K,
Gressner AM . Modulation of transforming growth factor beta
response and signaling during transdifferentiation of rat
hepatic stellate cells to myofibroblasts. Hepatology 2000; 31:
1094–1106.


Article  CAS  PubMed  Google Scholar 
35. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG et al.
An oral endothelin-A receptor antagonist blocks collagen
synthesis and deposition in advanced rat liver fibrosis.
Gastroenterology 2000; 118: 1169–1178.
Article  CAS  PubMed  Google Scholar 
36. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L,
Gaggiotti G et al. Insulin and insulin-like growth factor-1
stimulate proliferation and type I collagen accumulation by
human hepatic stellate cells: differential effects on signal
transduction pathways. Hepatology 1999; 29: 1743–1751.
Article  CAS  PubMed  Google Scholar 
37. Cui XS, Donehower LA . Differential gene expression in mouse
mammary adenocarcinomas in the presence and absence of
wild type p53. Oncogene 2000; 19: 5988–5996.
Article  CAS  PubMed  Google Scholar 
38. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G,
Edwards D et al. Comparative oncogenomics identifies breast
tumors enriched in functional tumor-initiating cells. Proc Natl
Acad Sci USA 2012; 109: 2778–2783.
Article  CAS  PubMed  Google Scholar 
39. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S,
Yang J et al. Core epithelial-to-mesenchymal transition
interactome gene-expression signature is associated with
claudin-low and metaplastic breast cancer subtypes. Proc Natl
Acad Sci USA 2010; 107: 15449–15454.
Article  CAS  PubMed  PubMed Central  Google Scholar 
40. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J,
Hu Z et al. Identification of conserved gene expression
features between murine mammary carcinoma models and
human breast tumors. Genome Biol 2007; 8: R76.


Article  PubMed  PubMed Central  Google Scholar 
41. Prat A, Parker JS, Karginova O, Fan C, Livasy C,
Herschkowitz JI et al. Phenotypic and molecular
characterization of the claudin-low intrinsic subtype of breast
cancer. Breast Cancer Res 2010; 12: R68.
Article  PubMed  PubMed Central  Google Scholar 
42. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K et
al. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth
of ovarian clear cell carcinoma in a PEA-15-dependent
manner in a mouse xenograft model. Mol Cancer Ther 2012;
11: 360–369.
Article  CAS  PubMed  Google Scholar 
43. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T,
Mabuchi Y et al. c-MYC overexpression with loss of Ink4a/Arf
transforms bone marrow stromal cells into osteosarcoma
accompanied by loss of adipogenesis. Oncogene 2010; 29:
5687–5699.
Article  CAS  PubMed  Google Scholar 
44. Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J
et al. Ink4a and Arf are crucial factors in the determination of
the cell of origin and the therapeutic sensitivity of Myc-
induced mouse lymphoid tumor. Oncogene 2012; 31: 2849–
2861.
Article  CAS  PubMed  Google Scholar 
45. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka
T et al. Retrovirus-mediated gene transfer and expression
cloning: powerful tools in functional genomics. Exp Hematol
2003; 31: 1007–1014.
Article  CAS  PubMed  Google Scholar 
46. Kai K, Nagano O, Sugihara E, Arima Y, Sampetrean O,
Ishimoto T et al. Maintenance of HCT116 colon cancer cell


line conforms to a stochastic model but not a cancer stem cell
model. Cancer Sci 2009; 100: 2275–2282.
Article  CAS  PubMed  Google Scholar 
47. Kai K, Zhang Z, Yamashita H, Yamamoto Y, Miura Y, Iwase H
. Loss of heterozygosity at the ATBF1-A locus located in the
16q22 minimal region in breast cancer. BMC Cancer 2008; 8:
262.
Article  PubMed  PubMed Central  Google Scholar 
Download references
Acknowledgements
We thank N Suzuki, Y Ito and S Hayashi for excellent animal
husbandry, I Ishimatsu for expert assistance with histology and K
Hashimoto for expert help in the flow cytometry lab. We thank T
Suda and MC Hung for invaluable discussions. Thanks are also
owed to M Fujiwara for expert help with microarray analysis, T
Ishimoto for technical help with confocal microscopy and SC
Patterson for editorial assistance. This work was supported by
grants from the Japan Society for the Promotion of Science, Japan
(to KK and HS). KK was supported by the program ‘Strategic Young
Researcher Overseas Visits Program for Accelerating Brain
Circulation’ by the Ministry of Education, Culture, Sports, Science
and Technology, Japan. This research was also supported in part by
the US National Institutes of Health through MD Anderson's Cancer
Center Support Grant (5 P30 CA016672-36), grant R01
CA123318-01A1 (to NTU) and by the Nellie B Connally Breast
Cancer Research Fund and a donation from Mr and Mrs Sidney J
Jansma, Jr.
Author information
Authors and Affiliations


1. Breast Cancer Translational Research Laboratory, The
University of Texas MD Anderson Cancer Center, Houston,
TX, USA
K Kai, C Bartholomeusz, L Pusztai & N T Ueno
2. Department of Breast Medical Oncology, The University of
Texas MD Anderson Cancer Center, Houston, TX, USA
K Kai, T Iwamoto, C Bartholomeusz, G N Hortobagyi, L
Pusztai & N T Ueno
3. Division of Gene Regulation, Institute for Advanced Medical
Research, School of Medicine, Keio University, Tokyo, Japan
K Kai, T Kobayashi, Y Arima, Y Takamoto, N Ohnishi & H
Saya
4. Division of Pathology, The Cancer Institute of the Japanese
Foundation for Cancer Research, Tokyo, Japan
R Horii & F Akiyama
Authors
1. K Kai
View author publications
Search author on:PubMed Google Scholar
2. T Iwamoto
View author publications
Search author on:PubMed Google Scholar
3. T Kobayashi
View author publications
Search author on:PubMed Google Scholar
4. Y Arima
View author publications


Search author on:PubMed Google Scholar
5. Y Takamoto
View author publications
Search author on:PubMed Google Scholar
6. N Ohnishi
View author publications
Search author on:PubMed Google Scholar
7. C Bartholomeusz
View author publications
Search author on:PubMed Google Scholar
8. R Horii
View author publications
Search author on:PubMed Google Scholar
9. F Akiyama
View author publications
Search author on:PubMed Google Scholar
10. G N Hortobagyi
View author publications
Search author on:PubMed Google Scholar
11. L Pusztai
View author publications
Search author on:PubMed Google Scholar
12. H Saya
View author publications
Search author on:PubMed Google Scholar
13. N T Ueno


View author publications
Search author on:PubMed Google Scholar
Corresponding authors
Correspondence to H Saya or N T Ueno.
Ethics declarations
Competing interests
The authors declares no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the
Oncogene website
Supplementary information
Supplementary Figures (PDF 114752 kb)
Supplementary Table S1 (DOC 65 kb)
Supplementary Table S2 (XLS 43 kb)
Supplementary Information (PDF 22 kb)
Rights and permissions
Reprints and permissions


About this article
Cite this article
Kai, K., Iwamoto, T., Kobayashi, T. et al. Ink4a/Arf−/− and
HRAS(G12V) transform mouse mammary cells into triple-negative
breast cancer containing tumorigenic CD49f− quiescent cells.
Oncogene 33, 440–448 (2014). https://doi.org/10.1038/
onc.2012.609
Download citation
•  Received: 09 July 2012
•  Revised: 25 October 2012
•  Accepted: 12 November 2012
•  Published: 04 February 2013
•  Issue date: 23 January 2014
•  DOI: https://doi.org/10.1038/onc.2012.609
Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
Keywords
•  Ink4a/Arf


•  HRAS(G12V)
•  Triple-negative breast cancer
•  Intratumoral heterogeneity
•  Tumor-initiating cell
This article is cited by
•  CSF-1/CSF-1R axis is associated with epithelial/
mesenchymal hybrid phenotype in epithelial-like
inflammatory breast cancer
○  Kazuharu Kai
○  Takayuki Iwamoto
○  Naoto T. Ueno
Scientific Reports (2018)
•  Insulin-like growth factor 1 receptor activation
promotes mammary gland tumor development
by increasing glycolysis and promoting biomass
production
○  Bas ter Braak
○  Christine L. Siezen
○  Bob van de Water
Breast Cancer Research (2017)
 Access through your institution
Buy or subscribe
Advertisement
[image]
Explore content


•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Current issue
•  Collections
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Journal Information
•  About the Editors
•  Contact
•  For Advertisers
•  Subscribe
•  Open Access Fees and Funding
Publish with us
•  For Authors & Referees
•  Language editing services
•  Open access funding
•  Submit manuscript
Search
Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search


Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Oncogene (Oncogene)
ISSN 1476-5594 (online)
ISSN 0950-9232 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access
Author & Researcher services
•  Reprints & permissions
•  Research data


•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies
•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights


[image]
© 2025 Springer Nature Limited
[image]


